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NHE3 is the apically located Na1/H1 exchanger in the
gut and in the renal proximal tubule. Acute inhibition of
this transporter by cAMP requires the presence of either of two NHE3-associated proteins, NHERF or
E3KARP. It has been suggested that these proteins either directly regulate NHE3 activity after being phosphorylated by protein kinase A (PKA) or that they may
serve as adapters that localize PKA near NHE3. We studied the role of NHERF and E3KARP in opossum kidney
cells, which endogenously express NHE3, NHERF, and
ezrin and display cAMP-dependent inhibition of NHE3.
In vivo phosphorylation studies showed that NHERF is a
phosphoprotein under basal conditions, but does not
change its phosphorylation state after 8-bromo-cAMP
treatment, and that E3KARP is not phosphorylated at
all. Co-immunoprecipitation showed that NHERF and
E3KARP bind both NHE3 and ezrin. Using cAMP analogs it was demonstrated that NHE3 activity, measured
as sodium-dependent recovery of the intracellular pH
after intracellular acidification, is inhibited by PKA
type II. Because others have shown that ezrin binds PKA
type II and that NHE3 is phosphorylated by PKA we
suggest that NHERF and E3KARP are adapters that link
NHE3 to ezrin, thereby localizing PKA near NHE3 to
allow NHE3 phosphorylation.
NHE31 is the apically located Na1/H1 exchanger isoform
1
2
that together with a Cl2/HCO2
3 exchanger or a Na /HCO3
co-transporter, respectively, mediates the majority of NaCl or
NaHCO3 absorption in the ileum and proximal colon and in the
proximal tubule (1, 2). Cyclic AMP is one of the major intracellular messengers mediating the inhibition of NHE3 (1, 3). Two
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models of how NHE3 is inhibited by cAMP have evolved: the
first model proposes that NHE3 is regulated through direct
phosphorylation of the transport protein. This model is based
on findings that in AP1 cells treatment with 8-Br-cAMP results
in the phosphorylation of NHE3 that parallels the inhibition of
transport activity (4, 5). The other model proposes that regulatory proteins are required to transduce cellular signals between protein kinase A and NHE3 (6, 7). The existence of one
or more regulatory proteins was suggested based on the finding
that in solubilized rabbit renal brush-border a protein fraction
that was required for regulation of NHE3 could be separated
from NHE3 itself (6), and that in PS120 fibroblasts several
signals that regulate NHE3 did not change the phosphorylation state of NHE3 (7). It was speculated that such regulatory
proteins would be the substrate for protein kinases (6, 7) and
that they would interact with NHE3 in a phosphorylation dependent manner, resulting in a change of NHE3 activity. It is
not known whether these two mechanisms are independent
processes or complementary in that both the regulatory proteins and NHE3 are phosphorylated in response to cAMP.
Two closely related regulatory proteins of NHE3, NHERF
(NHE regulatory factor), and E3KARP (NHE3 kinase A regulatory protein), have recently been identified (8, 9). We previously showed that there is a requirement for the presence of
NHERF or E3KARP for the cAMP-induced inhibition of NHE3
to occur (9). However, the mechanism by which these regulatory proteins facilitate cAMP inhibition of NHE3 is not understood. These regulatory proteins may induce a conformational
change of NHE3 or alternatively may function to physically
bring PKA near NHE3, thereby allowing phosphorylation of
NHE3 to occur. In the latter mode, the regulatory proteins
could act as direct anchors for PKA, known as A kinase anchoring proteins (AKAP) (10), or they could be adapters linking
NHE3 to other molecules that interact with PKA. These models
appear attractive because NHERF and E3KARP share their
highest homology along two PDZ domains, which are modules
for protein-protein interaction and which have been shown to
be involved in the linking of membrane proteins to signaling
complexes in other systems (11).
Here we report that NHERF and E3KARP are not substrates
for PKA and therefore do not directly regulate NHE3 activity.
Instead NHERF and E3KARP are shown to be adapters between the cytoskeletal protein ezrin and NHE3. Because ezrin
is an AKAP we propose that the regulatory proteins indirectly
localize PKA type II near NHE3 and thereby provide specificity
in the PKA signaling pathway by co-localizing PKA and its
substrate NHE3.
EXPERIMENTAL PROCEDURES

Expression of Recombinant Proteins—For bacterial expression the
region corresponding to base pairs 41 to 1377 of E3KARP was amplified
by polymerase chain reaction and cloned into pET30a (Novagen). Fulllength NHERF was used as described (12). Recombinant His-tagged
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proteins were expressed in Escherichia coli strain BL21 and purified by
affinity to Ni21-NTA resin as suggested by the manufacturer (Qiagen).
An expression construct of the entire C terminus of rat NHE3 (amino
acids 405 to 831) as a MBP fusion protein was the generous gift of Dr.
O. Moe (5). The MBP fusion protein was induced and expressed at 30 °C
and partially purified on amylose resin according to the recommendations of the manufacturer (New England Biolabs). This is referred to as
MBP-NHE3C.
Cell Culture and Transfection of Cells—OK cells between passage 53
and 73 were grown in Dulbecco’s modified Eagle’s medium/F-12 supplemented with 10% fetal calf serum, 100 mg/ml streptomycin, and 100
units/ml penicillin in 95% air, 5% CO2. For expression in OK cells,
NHERF, and E3KARP were cloned into pcDNA3.1HisA and pcDNA3.
1HisC (Invitrogen), respectively, resulting in pcDNA3.1His/E3KARP
and pcDNA3.1His/NHERF. OK cells were transfected with pcDNA3.
1His/E3KARP or pcDNA3.1His/NHERF using LipofectAMINE (Life
Technologies, Inc.) and clonal cell lines expressing the recombinant
fusion proteins were established by serial dilution. These cells are
referred to as OK/NHERF and OK/E3KARP, respectively.
PS120 fibroblasts were grown as described previously (7, 9). For
expression in PS120 fibroblasts the entire construct of His- and Stagged NHERF or E3KARP, respectively, was subcloned from pET30a
into the expression vector pMT3 (Genetics Institute), resulting in
pMT3/NHERF-HS and pMT/E3KARP-HS. PS120/NHE3V fibroblasts,
in which NHE3 carries a C-terminal VSVG tag (9), were co-transfected
using Lipofectin (GicoLife Technologies, Inc.) with pMT3/NHERF-HS
or pMT/E3KARP-HS and pPol2 for selection by hygromycin (600 units/
ml). Clonal cell lines were established by serial dilution and are referred
to as PS120/NHE3V/NHERF-HS and PS120/NHE3V/E3KARP-HS,
respectively.
In Vivo Phosphorylation—OK cells were grown to confluence on
tissue culture plates and then serum starved for 3 days. After two
washes with phosphate-free media, the cells were incubated for 3 h in
phosphate-free media plus 0.8 mCi/ml [32P]orthophosphoric acid (2.4
mCi total per plate). After two washes with phosphate-free media, the
cells were further incubated for 15 min in the presence or absence of 300
mM 8-Br-cAMP. All subsequent steps were carried out at 4 °C. Cells
were lysed in 400 ml of 8 M urea, 100 mM sodium phosphate, pH 8.0
(buffer B), plus 5 mM b-mercaptoethanol and 1% Triton X-100. The
lysate was cleared by centrifugation at 16,000 3 g for 30 min. The
His-tagged fusion proteins were then purified by incubation of the
lysate with 20 ml of Ni21-NTA resin for 1 h followed by washing 3 times
with buffer B plus 1% Triton X-100 and 3 times with buffer B titrated
to pH 6.3. The fusion proteins were separated from the beads using 100
mM EDTA and 2 3 Laemmli sample buffer. Proteins were separated by
8.5% SDS-PAGE, transferred to nitrocellulose, and probed by anti-sera
against either NHERF (Ab-RF) (13) or E3KARP (Ab2570) (14). Relative
amounts of the fusion proteins were determined by enhanced chemiluminescence (Renaissance Reagent plus, NEN Life Science Products
Inc.) and at least two separate, nonsaturating exposures were quantified using a densitometer (Molecular Dynamics). [32P] signals from the
same membranes were then quantified using a PhosphorImager (Molecular Dynamics). The data were analyzed using ImageQuant (Molecular Dynamics). For two-dimensional phosphopeptide mapping, bands
were cut out of dried SDS-PAGE gels and digested with 10 mg of
chymotrypsin according to a standard method (15). Digested peptides
were separated on thin layer chromatography plates and the plates
were analyzed by PhosphorImager.
For isoelectric focusing, the purified material was separated from the
Ni21-NTA resin and then concentrated in 8 M urea, 5% b mercaptoethanol, 0.002% bromphenol blue over a spin filter (10-kDa molecular mass
cut off; Millipore): 2% Triton X-100 and 5% ampholyte 3/10 were then
added to the resulting sample of 40 ml. The tube gels consisted of 4%
acrylamide, 9.5 M urea, 2% Triton X-100, and 5% (v/v) ampholyte 3/10
(Bio-Rad). After pre-electrophoresis, IEF was carried out for 3.5 h at
750 V. Separation in the second dimension, immunoblotting, and autoradiography were carried out as described above.
pHi Measurements—To study intracellular pH (pHi) using the ratiofluorometric, pH-sensitive dye BCECF, cells were seeded on glass coverslips, grown to confluence, and then serum starved for 3 days. Cells
were dye-loaded for 20 min with 6.5 mM BCECF/AM in 130 mM NaCl/
pHi buffer (20 mM HEPES, 5 mM KCl, 1 mM tetramethylammoniumPO4, 2 mM CaCl2, 1 mM MgSO4). The coverslip was mounted in a
perfusion cuvette heated to 30 °C as described earlier (16). Cells were
acidified by ammonium prepulse in 40 mM NH4Cl, 90 mM NaCl/pHi
buffer for 4 min and subsequently perfused with 130 mM tetramethylammonium-Cl/pHi buffer for 200 s. 130 mM NaCl was then reintroduced
and the sodium-dependent pHi recovery was recorded as described

29973

previously (16). At the end of each experiment the fluorescence ratio
was calibrated to pHi using the high potassium/nigericin method at the
extracellular pH of 6.0, 6.3, and 7.2. Slopes were calculated along the
pHi recovery by linear least square analysis over a minimum of 9 s.
When indicated, 8-Br-cAMP and the cAMP analogues (Biolog) were
present during the prepulse period.
RII Overlay—Blot overlays for the detection of AKAP were done
using His-tagged E3KARP and NHERF and MBP-NHE3C as described
previously (17).
Immunoprecipitation—OK or PS120 cells were washed twice in phosphate-buffered saline, scraped, and lysed in lysis buffer, containing 50
mM Tris, 100 mM NaCl, 50 mM sodium fluoride, 10 mM sodium pyrophosphate, 1 mM EDTA, 1 mM EGTA, pH 7.5, 1% Triton X-100, and
protease inhibitors (0.1 mM phenylmethylsulfonyl fluoride, 0.1 mM
phenanthrolidine, 5 mg/ml aprotinin, 5 mg/ml leupeptin). The crude
lysate was spun at 16,000 3 g for 30 min. This lysate was cleared by
incubation with 30 ml of protein-A Sepharose for 1 h and the supernatant was then incubated overnight with appropriate antisera. Immuncomplexes were purified with 40 ml of protein-A-Sepharose, washed 3
times in lysis buffer and 3 times in lysis buffer without Triton X-100.
Bound immuncomplexes were eluted by incubating the beads in Laemmli sample buffer for 10 min at 85 °C and were then separated by
SDS-PAGE. The proteins were then transferred to nitrocellulose and
immunoblotted using the indicated antibodies.
RESULTS

8-Br-cAMP Changes the pHi Dependence of NHE3 through
Activation of PKA Type II—In order to study the inhibitory
effect of cAMP on the transport kinetics of Na1/H1 exchange,
OK cells were acidified to pHi 6.0 and the sodium-dependent
pHi recovery was recorded. Fig. 1A shows a typical trace and
the inhibitory effect of 100 mM 8-Br-cAMP. Fig. 1B shows that
sodium-dependent pHi recovery was dose-dependently inhibited by 8-Br-cAMP with a maximal effect seen at 100 mM 8-BrcAMP. Therefore all further fluorometric studies were done
using 100 mM 8-Br-cAMP.
We measured the pHi recovery rate at different intracellular
pH in the absence and presence of 100 mM 8-Br-cAMP (Fig. 1C)
and calculated the relative inhibition of the pHi recovery by 100
mM 8-Br-cAMP at different pHi (Fig. 1D). At pHi 6.0, 100 mM
8-Br-cAMP resulted in only 15% inhibition of sodium-dependent pHi recovery, but at more alkaline pHi a stronger inhibition
(50% at pHi 7.0, 70% at pHi 7.3) became apparent (Fig. 1D).
Thus our data indicate that 8-Br-cAMP changed the pHi dependence of the transporter; the small inhibition even at the
most acidic pHi studied suggests that a small change in Vmax
may also be present.
The participation of NHE1, which is regulated by changes in
its pHi dependence (16, 18), in the sodium-dependent pHi recovery, was ruled out by applying 20 mM Hoe694 during the pHi
recovery. Twenty mM Hoe694, which blocks NHE1 but not
NHE3 (18), resulted in less than 10% inhibition (data not
shown). This is consistent with previous reports that NHE1 is
absent from OK cells (19, 20). Any influence of 100 mM 8-BrcAMP on another, as yet unidentified, sodium-dependent proton-exporting mechanism was also ruled out, because in the
presence of 1 mM amiloride, which inhibited sodium-dependent
pHi recovery by 80 –95%, 100 mM 8-Br-cAMP had no additional
inhibitory effect (data not shown).
Two types of PKA, type I (PKA I) and type II (PKA II),
display different biochemical properties due to differences in
their regulatory (R) subunits (10). Each R subunit contains two
cAMP-binding sites to which cAMP bind cooperatively (10).
Until recently it was believed that only PKA II is membrane
bound and affects proteins in or near membranes (10) but more
recently examples of membrane bound PKA I have been described (21, 22). In pilot experiments we found that OK cells
express both PKA isoforms, making it necessary to determine
which isoform is responsible for the regulation of NHE3. We
therefore used combinations of site-specific cAMP analogs to
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FIG. 1. 8-Br-cAMP inhibits Na1/H1
exchange dose dependently through
a change of the pHi dependence of
NHE3. A, representative trace of cAMPdependent inhibition of sodium-dependent pHi recovery. OK cells were acidified
by ammonium prepulse (40 mM) and subsequent perfusion with tetramethylammonium-Cl. pHi recovery was facilitated
by re-addition of NaCl (130 mM) (solid
line). When indicated 100 mM 8-Br-cAMP
was present during the ammonium prepulse (dotted line). B, dose response to
8-Br-cAMP. Different concentrations of
8-Br-cAMP were applied during the period of the ammonium prepulse and the
effect on sodium-dependent pHi recovery
was recorded. C, pHi dependence of the
8-Br-cAMP effect. pHi recovery rates
(DpHi/Dt) were calculated over short time
intervals during the pHi recovery under
control conditions (f) and after treatment
with 100 mM 8-Br-cAMP (E). The recovery
rates (DpHi/Dt) are plotted at different intracellular pH. D, from the data shown in
panel C, the inhibition induced by 100 mM
8-Br-cAMP at different pHi was calculated.

TABLE I
Relative affinities of cAMP analogs used in this study
The values indicate the binding affinity of cAMP analogs for the two
cAMP-bindings sites (site A and site B) in the regulatory subunits of
both PKA isoforms (type I and type II), all compared to cAMP (24). The
combination of 8-Pip-cAMP and 8-AHA-cAMP was used to preferentially acitvate PKA I and the combination of 8-Pip-cAMP and 6-BenzcAMP was used to preferentially activate PKA II.
PKA type I

PKA type II

cAMP analog

8-AHA-cAMP
6-Benz-cAMP
8-Pip-cAMP

Site A

Site B

Site A

Site B

0.11
3.5
2.3

1.6
0.18
0.065

0.021
4.1
0.046

0.29
0.034
3.2

preferentially activate either of the two isoforms (Table I).
These cell-permeable, relatively phosphodiesterase-resistant
drugs bind with different affinities to the two cAMP-binding
sites of each PKA regulatory subunit. Therefore combinations
of cAMP analogs can be chosen, that synergistically activate
either PKA I or II, although at high concentrations these analogs activate both PKA isoforms (23, 24). 8-Pip-cAMP was used
as the common agent at a “priming” concentration of 10 mM,
which alone had no effect on sodium-dependent pHi recovery
(Fig. 2). To preferentially activate PKA I or PKA II, 8-PipcAMP was combined with either 8-AHA-cAMP or 6-BenzcAMP, respectively. Consistent with the inhibition by 8-BrcAMP, application of these combinations inhibited the sodiumdependent pHi recovery also by a change in the pHi dependence
(data not shown). For quantification, the extent of inhibition of
the pHi recovery by the cAMP analogs was compared with that
by 100 mM 8-Br-cAMP at pHi 7.0. As shown in Fig. 2, the
combination of 8-Pip-cAMP and 6-Benz-cAMP, directed at PKA
II, resulted in a larger extent of inhibition than the combination of 8-Pip-cAMP and 8-AHA-cAMP, which is directed at PKA
I. The inhibitory effect of the PKA I directed combination is
probably due to some “cross-activation” of PKA II (see Table I).
8-Pip-cAMP and 6-Benz-cAMP also displayed cooperativity in
that addition of 8-Pip-cAMP at a priming concentration of 10
mM significantly increased the effect of 6-Benz-cAMP. A smaller
degree of cooperativity was also seen with the combination of
8-Pip-cAMP and 8-AHA-cAMP, but it did not achieve statistical

FIG. 2. cAMP inhibits NHE3 through PKA type II. OK cells were
treated with the indicated concentrations of 8-Pip-cAMP, 8-AHA-cAMP,
and 6-Benz-cAMP either individually or in combinations known to
activate preferentially PKA I (8-Pip-cAMP plus 8-AHA-cAMP, upper
panel) or PKA II (8-Pip-cAMP plus 6-Benz-cAMP, lower panel). To
quantitatively compare the inhibition of sodium-dependent pHi recovery induced by these compounds to the inhibition induced by 100 mM
8-Br-cAMP pHi recovery rates were calculated at pHi 7.0. n 5 3–15.
Values were compared by unpaired t test.

significance. These data suggest that the inhibition of NHE3 is
mediated by PKA II.
In Vivo Phosphorylation of NHERF and E3KARP—We next
determined whether the cAMP mediated inhibition of NHE3
involves changes in the phosphorylation state of NHERF and
E3KARP in vivo. Because NHERF and E3KARP have approximately the same molecular mass as IgG, thereby rendering
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FIG. 4. Two-dimensional phosphopeptide mapping of NHERF.
The bands corresponding to NHERF purified from OK/NHERF cells
under basal conditions (2cAMP) or after treatment with 300 mM 8-BrcAMP were cut out of the nitrocellulose membranes and digested with
chymotrypsin. The phosphopeptides were spotted on thin-layer chromatography plates and separated by electrophoresis and chromatography. Representative autoradiograms of four experiments are shown.

FIG. 3. In vivo phosphorylation of NHERF. Wild type OK, OK/
NHERF, and OK/E3KARP cells were 32P-labeled in vivo. Where indicated the cells were treated with 300 mM 8-Br-cAMP for 10 min at the
end of the labeling period. NHERF or E3KARP were purified as Histagged fusion proteins on Ni21-NTA resins. Untransfected wild type OK
cells served as a control for the specificity of purification. Purified
proteins were separated on SDS-PAGE, blotted onto nitrocellulose, and
the autoradiogram was obtained (upper panel). The respective parts of
the membrane were then probed by AbRF or Ab2570 to determine the
amount of purified protein in the presence or absence of cAMP (compare
lane 2 with lane 3 and lane 6 with lane 7) (lower panel). Recombinant
NHERF and E3KARP (lanes 1 and 8) served as size controls for the
Western blot. The arrows indicate the molecular mass of NHERF and
E3KARP. Representatives of five experiments are shown.

protein quantification by Western blot following immunoprecipitation difficult, the regulatory proteins were expressed as
His-tagged fusion proteins to allow affinity purification on
Ni21-NTA resins. OK cells were labeled with 32P in vivo and
the recombinant His-tagged regulatory proteins were purified
using Ni21-NTA resins. The amount of 32P incorporated was
determined by a PhosphorImager and was corrected for the
amount of protein as determined by Western immunoblot. Fig.
3 shows the autoradiogram of phosphoproteins purified from
labeled wild type OK, OK/NHERF, and OK/E3KARP cells and
the corresponding Western blots. The autoradiogram in Fig. 3
shows that His-tagged NHERF was purified from OK/NHERF
as a phosphoprotein under basal conditions. Following treatment with 8-Br-cAMP, the amount of 32P incorporated into
NHERF did not change significantly (0.99 6 0.03-fold relative
to untreated cells). Normalization of the 32P radioactivity to the
amount of NHERF purified also revealed that the phosphorylation level of NHERF did not change in response to 8-Br-cAMP
(1.05 6 0.03-fold relative to untreated cells).
Changes in the phosphorylation state may be masked either
by a high degree of basal phosphorylation or by an increase in
phosphorylation at one site and a concomitant decrease at
another site. To address this possibility, the NHERF bands
were cut out, digested with chymotrypsin, and two-dimensional
phosphopeptide mapping was performed (Fig. 4). In four independent experiments two major and one minor spot were detected and all had identical intensities under basal conditions
and after 8-Br-cAMP treatment. This rules out the possibility
of masked changes in the phosphorylation state of NHERF.
E3KARP migrated in the SDS-PAGE gels together with a
phosphoprotein that was co-purified as a contaminant from
wild type OK cells (compare lanes 3 and 4 to lanes 5 and 6 of the
autoradiogram in Fig. 3) making it difficult to judge its phos-

FIG. 5. Two-dimensional PAGE of proteins purified by Nickel
agarose from OK/E3KARP cells. E3KARP was purified by Ni21-NTA
resins under basal conditions or after treatment with 300 mM 8-BrcAMP for 10 min of OK/E3KARP cells labeled in vivo with 32P. The
purified proteins were separated first by isoelectric focusing (IEF) and
then by conventional SDS-PAGE and finally transferred to nitrocellulose for autoradiography and subsequent Western blot (upper panel).
Representative autoradiograms are shown. OK/NHERF cells served as
a positive control (lower panel). The arrows indicate the location where
E3KARP or NHERF were detected by Western blot.

phorylation state by the one-dimensional approach. Therefore
proteins purified from OK/E3KARP cells were separated by
two-dimensional PAGE. No phosphoprotein signal was detected by PhosphorImager at the location were E3KARP was
detected by Western blot under basal conditions or after 8-BrcAMP treatment (Fig. 5). By contrast, NHERF, which was run
as a positive control, again showed a phosphoprotein spot at the
location where the protein was detected by Western. This indicates that E3KARP is neither constitutively phosphorylated
nor phosphorylated after 8-Br-cAMP treatment.
NHERF and E3KARP Are Not AKAPs—Based on our finding
that NHE3 is inhibited by cAMP through an action of PKA II
but NHERF and E3KARP are not direct targets for phosphorylation, we determined if NHERF and E3KARP function as
AKAPs. AKAPs are defined by their ability to bind the regulatory subunit (RII) of PKA II (17). His-tagged NHERF and
E3KARP transferred onto nitrocellulose were probed with 32Plabeled RII. Fig. 6 shows that NHERF and E3KARP both
yielded positive signals although at much weaker intensity
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FIG. 6. [32P] RII overlay assay on recombinant NHERF,
E3KARP, and NHE3C. His- and S-tagged E3KARP and NHERF and
MBP-NHE3C were separated on PAGE and blotted onto nitrocellulose.
The membranes were probed with 32P-labeled RII in an overlay assay to
detect AKAP. Where indicated the inhibitory peptide Ht31, which disrupts the RII AKAP interaction, was present. MAP-2 served as a positive control. The arrow denotes the molecular mass of MBP-NHE3C.

than microtubule-associated protein 2 (MAP-2), which was
used as a positive control (25). By contrast, 32P-labeled RII did
not bind to MBP-NHEC3. To test whether the signals from
NHERF and E3KARP are specific, the RII overlay assay was
performed in the presence of 1.4 mM Ht31, a peptide which
specifically disrupts the binding of RII to AKAP (26). In the
presence of Ht31, the binding of 32P-labeled RII to MAP-2 was
almost completely blocked whereas the weak binding to
NHERF and E3KARP remained unchanged (Fig. 6). This indicates that the RII subunit nonspecifically bound to E3KARP
and NHERF. We conclude from these data that neither
NHERF/E3KARP nor the cytoplasmic tail of NHE3 functions
as AKAP.
NHERF and E3KARP Bind Ezrin and NHE3—In placental
brush-border, human NHERF (called EBP50) has recently
been identified as a protein that binds to the cytoskeletal protein ezrin (27). In parietal cells ezrin functions as an AKAP
(28). We therefore tested whether NHERF and E3KARP interact with both ezrin and NHE3. NHERF and E3KARP were
immunoprecipitated and immuncomplexes were tested for the
presence of NHE3 or ezrin by Western analysis.
Fig. 7 shows that ezrin was co-immunoprecipitated with
NHERF from both wild type OK and OK/NHERF cells. However, the amount of ezrin was clearly higher in the immunoprecipitate from OK/NHERF cells, which is consistent with the
larger amount of NHERF expressed in the transfected cells.
Similarly, ezrin was co-immunoprecipitated with E3KARP
from OK/E3KARP cells, demonstrating that E3KARP also
binds ezrin. However, we could not clearly determine whether
NHE3 also co-immunoprecipitated with NHERF or E3KARP in
OK cells. This is mainly because both the antibody against OK
NHE3 (20) and the antibodies against NHERF and E3KARP
are raised in the same species, i.e. rabbit, which led to considerable background.
To overcome this limitation, we used PS120 cells transfected
with NHE3V and either NHERF or E3KARP. In these cells
co-immunoprecipitated NHE3 was detected by a monoclonal
antibody against the VSVG tag. Fig. 8 shows that NHE3V was
co-immunoprecipitated with NHERF and E3KARP from
PS120/NHE3V/NHERF-HS and PS120/NHE3V/E3KARP-HS
cells, respectively. Fig. 8 shows that ezrin was also co-immunoprecipitated with NHERF and E3KARP from these cells.

FIG. 7. Co-immunoprecipitation of ezrin with NHERF and
E3KARP in OK cells. Lysates from wild type OKs, OK/NHERF, and
OK/E3KARP cells were immunoprecipitated with AbRF or Ab2570 (1).
Preimmune serum was used as a negative control (2). The precipitated
immuncomplexes were probed for the presence of ezrin by anti-ezrin
antibody. Representatives of four experiments are shown.

FIG. 8. Co-immunoprecipitation of NHE3 and ezrin with
NHERF and E3KARP in PS120 fibroblasts. Lysates from PS120/
NHE3V/NHERF-HS and PS120/NHE3V/E3KARP-HS fibroblasts were
immunoprecipitated with AbRF (left panels) or Ab2570 (right panels),
respectively (1). Preimmune serum was used as a negative control (2).
The isolated immuncomplexes were probed for the presence of NHE3 by
monoclonal anti-VSVG (upper panels) or anti-ezrin antibody (lower
panels).

DISCUSSION

OK Cells as a Model to Study the Role of NHERF and
E3KARP in the cAMP-mediated Inhibition of NHE3—The molecular mechanisms involved in the regulation of NHE3 have
been studied in a number of different models (3). In our and
other laboratories (4, 5, 9, 16) a number of studies have been
conducted in non-epithelial cells devoid of the ubiquitous
NHE1 and transfected with NHE3. This approach carries the
potential problem that proteins required for the regulation of
NHE3, such as parts of the signaling cascade, may be missing
or not appropriately located in these non-polarized cells. For
example, PS120 fibroblasts were shown to lack the regulatory
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proteins NHERF and E3KARP that are required for the cAMPdependent inhibition of NHE3 (9).
For the present study we have chosen opossum kidney (OK)
cells, which are derived from the renal proximal tubule, for the
following reasons: (a) OK cells are a polarized epithelial cell
line (19), that expresses only the NHE3 isoform of the known
Na1/H1 exchangers (19, 20). (b) NHE3 is inhibited by cAMP in
these cells (29), indicating that the machinery mediating this
process, although not fully understood, is present. (c) OK cells
express NHERF (30). (d) OK cells also endogenously express
ezrin just like proximal tubule cells (31). These characteristics
of OK cells make them an ideal physiological model to study the
role of NHERF in the cAMP-mediated inhibition of NHE3. In
order to study the role of E3KARP in this model we transfected
E3KARP into OK cells. Of note, mRNA for E3KARP is expressed in kidney (9), suggesting that E3KARP has a physiological role in the regulation of renal NHE3 as well.
Protein Kinase A Inhibits NHE3 by a Change of the pHi
Dependence of the Transporter—Na1/H1 exchange mediated by
all NHE isoforms is allosterically modified by the intracellular
pH (16). Second messenger-mediated regulation of NHE1 has
been shown to affect this pHi dependence, while regulation of
NHE2 and NHE3 in transfected PS120 fibroblasts by protein
kinase C, calmodulin/CaM kinase II, serum, and fibroblast
growth factor changes the Vmax of the transporters without
affecting their pHi dependence (16, 32). By contrast, we found
that in OK cells NHE3 is predominantly inhibited by cAMP
through a change in its pHi dependence. Because the initial pHi
recovery was very fast and the buffering capacity declined
considerably between pH 6.0 and 6.5 we could not reliably fit
the data to an allosteric Hill kinetic model. Instead pHi recovery rates were calculated at different pHi along the pHi recovery and the values from cells treated with 8-Br-cAMP were
then compared with the values of control cells. If inhibition
occurred by a change in Vmax, the relative inhibition should be
the same at every given pHi. By contrast, if the pHi dependence
was changed, this should be reflected in differing degrees of
inhibition at different pHi. Our data indicate that NHE3 is
predominantly inhibited by a change in its pHi dependence, but
we cannot rule out a small decrease in Vmax. The change in pHi
dependence is in agreement with the recent findings in NHE3transfected AP1 cells (4, 33) and with the earlier report by
Miller and Pollack (34), which showed the effect of 8-Br-cAMP
on the amiloride inhibitable 22Na1 uptake into OK cells
clamped to different pHi.
As the next step, we determined which PKA isoform mediates this process. For this we employed combinations of cAMP
analogs, that preferentially activate either PKA I or PKA II
(Table I) (23). We found that PKA II mediates the cAMP dependent inhibition of NHE3. The functional importance of PKA
II in the regulation of NHE3 is supported by the finding that
expression of a dominant negative regulatory subunit type II
abolishes cAMP regulation (35) and by identification of PKA II
in the apical membrane of proximal tubule cells (36).
The Phosphorylation State of NHERF and E3KARP Does Not
Change upon 8-Br-cAMP Treatment—Two lines of evidence
have suggested that not NHE3 itself but one or more associated
regulatory proteins of NHE3 may be the substrates for PKA
regulating NHE3. (a) Regulation of NHE3 in transfected PS120
cells by fibroblast growth factor or protein kinase C does not
involve direct phosphorylation of the transporter (7). (b) In
renal brush-border membranes a protein fraction that is necessary for cAMP inhibition of NHE3 can be separated from
NHE3 itself (6). NHERF could be such a substrate for PKA,
since it is necessary for cAMP-mediated inhibition of NHE3 (6,
9), contains at least one putative PKA concensus phosphoryla-
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FIG. 9. Proposed model for the role of NHERF and E3KARP in
the cAMP-mediated inhibition of NHE3. The regulatory proteins
work as adapters between NHE3 and ezrin. Ezrin is an AKAP. Upon
binding of cAMP to the regulatory subunit of PKA II, the catalytic
subunit is released and phosphorylates NHE3.

tion site (8), and has also been isolated as a phosphoprotein (6).
On the other hand, E3KARP which also mediates cAMP inhibition of NHE3 in PS120 cells, does not have a putative PKA
phosphorylation site (9). In addition, the recent finding of cAMPdependent phosphorylation of NHE3 at S605 in AP-1 cells (4)
raises the question of whether cAMP-dependent phosphorylation of the regulatory proteins is necessary for the regulation of
NHE3. Using in vivo phosphorylation, we found that neither
protein is a substrate for PKA. NHERF is a phosphoprotein
under basal conditions, consistent with a recent report (12).
But more importantly its phosphorylation state does not
change after treatment with 8-Br-cAMP. E3KARP is neither a
phosphoprotein under basal condition nor after treatment with
8-Br-cAMP. These data show that regulation of NHE3 does not
occur through a change in phosphorylation of the regulatory
proteins. If then, how do these regulatory proteins function in
the regulation of NHE3?
NHERF and E3KARP Are Not AKAPs but Are Linkers between NHE3 and the AKAP Ezrin—Our data discussed so far
show that NHERF and E3KARP are not substrates for PKA
but are involved in the inhibition of NHE3 by PKA II (9). It is
therefore plausible that the regulatory proteins function to
physically localize PKA II near NHE3. In many systems,
AKAPs localize PKAII in close proximity of its substrates (10),
but our data clearly indicate that NHERF and E3KARP are not
AKAPs and also that the C-terminal tail of NHE3 does not
function as an AKAP either. These negative results do not rule
out that the regulatory proteins may bind to yet another molecule that would function as an AKAP.
During the course of this study, an ezrin-binding protein of
50-kDa molecular mass, EBP50, was identified in placental
brush border (27). Cloning revealed that EBP50 is the human
homologue of NHERF. One function of ezrin is to link the actin
based cytoskeleton to the plasma membrane (27, 31), but so far
only three transmembrane proteins, CD44, CD43, and ICAM-2,
binding to ezrin have been identified (37). Therefore EBP50 has
been suggested to be an intermediate between ezrin and one or
several as yet unidentified transmembrane proteins (27). In the
present study we demonstrate that ezrin co-immunoprecipitates with NHERF and E3KARP in OK cells and in PS120
fibroblasts. NHE3 also co-immunoprecipitates with the regulatory proteins in PS120 fibroblasts. These results for the first
time demonstrate NHE3 as a transmembrane protein that is
linked to ezrin through one of the regulatory proteins (NHERF/
EBP50 or E3KARP). The biochemical details of the interaction
of NHERF (38) and E3KARP (14) with ezrin have recently been
described.
Ezrin has been identified as an AKAP in parietal cells (28).
We have confirmed this finding and also found that ezrin,
based on the RII overlay assay, is a weak AKAP (data not
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shown). Nevertheless we could co-immunoprecipitate RII with
NHERF (data not shown). One interpretation is that those
ezrin molecules that interact in vivo with the regulatory proteins also bind RII at the same time.
Taking the findings in the present study together with the
report by Kurashima et al. (4), we propose the following model
for the role of NHERF and E3KARP in the regulation of NHE3
(Fig. 9). The regulatory proteins link NHE3 to ezrin thereby
adding physical support to the microvillar structure. Furthermore, ezrin functions as an AKAP, thereby placing PKA II into
close proximity of NHE3. Upon stimulation by cAMP the catalytic subunit of PKA dissociates from the regulatory subunit
and phosphorylates NHE3 probably at the serine residue corresponding Ser-605 of rat NHE3. This phosphorylation results
in inhibition of transport activity by change in the pHi dependence of the transporter. In this model the function of the regulatory proteins is to co-localize NHE3 and PKA II.
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